Edwards Lifesciences | EW - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
Abbott USD 299M 231M 2026-06
Artivion USD 5.53M 589K 2025-12
AtriCure USD 1.21M 159K 2026-03
Baxter International USD 78M 20M 2026-03
Becton, Dickinson and Co. USD 132M 17M 2026-06
Boston Scientific USD 96M 6M 2026-06
Cooper Companies USD 21.5M 600K 2026-06
Dexcom USD 3.1M 1.1M 2026-03
Edwards Lifesciences USD 30M 5.9M 2026-06
Globus Medical USD 5.49B 48.7M 2026-06
ICU Medical USD 18.53M 2.11M 2026-03
Inogen 1.03M 384K 2025-03
Insulet USD 11M 3.7M 2026-06
Integra LifeSciences USD 22.99M 529K 2026-06
Intuitive Surgical USD 20.88B 765.6M 2026-06
J&J USD 43M 25M 2026-03
Medtronic USD 186M 10M 2026-06
Merit Medical Systems USD 12.12M 5.59M 2026-06
Stryker USD 47.93B 1.64B 2026-06
Tandem Diabetes Care USD 1.15B 808K 2026-06
Teleflex USD 27.95M 2.24M 2026-06
Zimmer Biomet Holdings USD 22.8B 22.73B 2026-06